Lal R - Search Results

1

Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice.

Califano R, Lal R, Lewanski C, Nicolson MC, Ottensmeier CH, Popat S, Hodgson M, Postmus PE. Califano R, et al. Among authors: lal r. Future Oncol. 2018 Oct;14(23):2415-2431. doi: 10.2217/fon-2018-0330. Epub 2018 Jul 6. Future Oncol. 2018. PMID: 29978725 Free article.

2

PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation.

Cree IA, Booton R, Cane P, Gosney J, Ibrahim M, Kerr K, Lal R, Lewanski C, Navani N, Nicholson AG, Nicolson M, Summers Y. Cree IA, et al. Among authors: lal r. Histopathology. 2016 Aug;69(2):177-86. doi: 10.1111/his.12996. Epub 2016 Jun 30. Histopathology. 2016. PMID: 27196116 Free article. Review.

3

Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.

Califano R, Greystoke A, Lal R, Thompson J, Popat S. Califano R, et al. Among authors: lal r. Lung Cancer. 2017 Sep;111:51-58. doi: 10.1016/j.lungcan.2017.06.004. Epub 2017 Jun 9. Lung Cancer. 2017. PMID: 28838397 Free article. Review.

4

Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK.

Califano R, Tariq N, Compton S, Fitzgerald DA, Harwood CA, Lal R, Lester J, McPhelim J, Mulatero C, Subramanian S, Thomas A, Thatcher N, Nicolson M. Califano R, et al. Among authors: lal r. Drugs. 2015 Aug;75(12):1335-48. doi: 10.1007/s40265-015-0434-6. Drugs. 2015. PMID: 26187773 Free PMC article. Review.

5

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.

Lee SM, Khan I, Upadhyay S, Lewanski C, Falk S, Skailes G, Marshall E, Woll PJ, Hatton M, Lal R, Jones R, Toy E, Chao D, Middleton G, Bulley S, Ngai Y, Rudd R, Hackshaw A, Boshoff C. Lee SM, et al. Among authors: lal r. Lancet Oncol. 2012 Nov;13(11):1161-70. doi: 10.1016/S1470-2045(12)70412-6. Epub 2012 Oct 16. Lancet Oncol. 2012. PMID: 23078958 Free PMC article. Clinical Trial.

6

The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy.

Lee SM, Upadhyay S, Lewanski C, Falk S, Skailes G, Woll PJ, Hatton M, Lal R, Jones R, Toy E, Rudd R, Ngai Y, Edwards A, Hackshaw A. Lee SM, et al. Among authors: lal r. Eur J Cancer. 2019 Oct;120:86-96. doi: 10.1016/j.ejca.2019.07.025. Epub 2019 Sep 6. Eur J Cancer. 2019. PMID: 31499384 Free PMC article. Clinical Trial.

7

Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer.

Lal R, Hillerdal GN, Shah RN, Crosse B, Thompson J, Nicolson M, Vikström A, Potter VA, Visseren-Grul C, Lorenzo M, D'yachkova Y, Bourayou N, Summers YJ. Lal R, et al. Lung Cancer. 2015 Aug;89(2):154-60. doi: 10.1016/j.lungcan.2015.05.003. Epub 2015 May 12. Lung Cancer. 2015. PMID: 26101013 Clinical Trial.

8

Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy.

Papa S, Popat S, Shah R, Prevost AT, Lal R, McLennan B, Cane P, Lang-Lazdunski L, Viney Z, Dunn JT, Barrington S, Landau D, Spicer J. Papa S, et al. Among authors: lal r. J Thorac Oncol. 2013 Jun;8(6):783-7. doi: 10.1097/JTO.0b013e31828c2b26. J Thorac Oncol. 2013. PMID: 23571475 Free article. Clinical Trial.

9

Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design.

Lal R, Bourayou N, Hillerdal G, Nicolson M, Vikstrom A, Lorenzo M, D'yachkova Y, Barriga S, Visseren-Grul C. Lal R, et al. Health Qual Life Outcomes. 2013 Oct 3;11:163. doi: 10.1186/1477-7525-11-163. Health Qual Life Outcomes. 2013. PMID: 24090033 Free PMC article. Clinical Trial.

10

Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer.

Fennell DA, Summers Y, Cadranel J, Benepal T, Christoph DC, Lal R, Das M, Maxwell F, Visseren-Grul C, Ferry D. Fennell DA, et al. Among authors: lal r. Cancer Treat Rev. 2016 Mar;44:42-50. doi: 10.1016/j.ctrv.2016.01.003. Epub 2016 Feb 4. Cancer Treat Rev. 2016. PMID: 26866673 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,220 results

Search Page